<DOC>
	<DOC>NCT00398840</DOC>
	<brief_summary>This is an open label, dose escalation study of ARQ 171 administered via intravenous infusion (IVI) into a peripheral vein weekly. Patients with advanced solid tumors, who are refractory to available therapy or for whom no standard systemic therapy exists, will be enrolled.</brief_summary>
	<brief_title>A Study of ARQ 171 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Signed written informed consent must be obtained and documented prior to studyspecific screening procedures. A histologically or cytologically confirmed advanced solid tumor ≥ 18 years of age Measurable disease as defined by Response Evaluation Criteria in Solid Tumors Karnofsky performance status ≥ 70% Male or female patients of childproducing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after participation. Females of childbearing potential must have a negative serum pregnancy test. Laboratory results must meet study criteria. Anticancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first infusion Surgery within 4 weeks prior to first infusion Known untreated brain metastases Pregnant or breastfeeding Uncontrolled intercurrent illness, or uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements Other cancer within the last five years, with the exception of adequately treated conebiopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>advanced solid tumors</keyword>
</DOC>